<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01783119</url>
  </required_header>
  <id_info>
    <org_study_id>REF.589</org_study_id>
    <nct_id>NCT01783119</nct_id>
  </id_info>
  <brief_title>Effect of Aloe Vera in the Inflammation of Patients With Mild Ulcerative Colitis</brief_title>
  <acronym>AVIUC</acronym>
  <official_title>Effect of Aloe Vera in the Inflammation of Patients With Mild Ulcerative Colitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Medical Sciences and Nutrition, Salvador Zubiran</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Medical Sciences and Nutrition, Salvador Zubiran</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Ulcerative Colitis (UC) belongs to the group of diseases called Inflammatory Bowel
      Disease (IBD) which is characterized by a chronic ulceration of the colon. The conventional
      treatment can have adverse effects and does not guarantee effectiveness in some patients
      requiring aggressive therapy using adjuvant therapy Aloe vera has been shown to have a
      beneficial effect in different disease, and have an anti-inflammatory effect in UC patients.
      Objective: Measuring the effect of the consumption of 200 ml of aloe vera gel daily for a
      period of three months, in the degree of inflammation in patients with mild UC based on Mayo
      scale and quantification of IL-6 in the colonic mucosa.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>August 2012</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Full Mayo Score</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Interleukine - 6</measure>
    <time_frame>3 months</time_frame>
    <description>Quantification in mucosal Biopsy</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Ulcerative Colitis</condition>
  <arm_group>
    <arm_group_label>Aloe Vera</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Consume 200 ml of aloe vera gel per day over a period of three months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>water</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Consume 200 ml of placebo per day over a period of three months</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Aloe Barbadensis Miller</intervention_name>
    <arm_group_label>Aloe Vera</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>placebo water</intervention_name>
    <arm_group_label>water</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with confirmed diagnosis by histopathology of Ulcerative Colitis with mild
             activity level clinical, Endoscopic and histological.

          -  Extent of disease: pancolitis, ulcerative proctitis and left.

          -  Being treated with 5 - aminosalicylates (5-ASA).

          -  Belonging to the National Institute of Medical Sciences and Nutrition &quot;Salvador
             Zubirán&quot;.

          -  Signed informed consent.

        Exclusion Criteria:

          -  Autoimmune diseases (lupus, HIV, cancer and any hepatitis).

          -  Another type of colitis (indeterminate, infectious drug and Crohn's Disease.

          -  Previous total colectomy.

          -  Body mass index less than 19.9 kg/m2 or greater than 40 kg/m2.

          -  Patients in remission histology, clinical and endoscopic.

          -  Under treatment with steroids, azathioprine, diuretics and anticoagulants.

          -  Use Aloe Vera or some natural therapy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>59 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jesús K Yamamoto-Furusho, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>INCMNSZ</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lizzette C Alfaro</last_name>
    <role>Principal Investigator</role>
    <affiliation>INCMNSZ</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jesús K. Yamamoto-Furusho, PhD,MD</last_name>
    <phone>+5554870900</phone>
    <phone_ext>2710</phone_ext>
    <email>kazuofurusho@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>National Institute of Medical Science and Nutrition, Salvador Zubirán</name>
      <address>
        <city>D.f.</city>
        <state>Tlalpan</state>
        <zip>14000</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jesús K Yamamoto-Furusho, MD, PhD</last_name>
      <phone>+5554870900</phone>
      <phone_ext>2710</phone_ext>
      <email>kazuofurusho@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <reference>
    <citation>Molodecky NA, Soon IS, Rabi DM, Ghali WA, Ferris M, Chernoff G, Benchimol EI, Panaccione R, Ghosh S, Barkema HW, Kaplan GG. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012 Jan;142(1):46-54.e42; quiz e30. doi: 10.1053/j.gastro.2011.10.001. Epub 2011 Oct 14. Review.</citation>
    <PMID>22001864</PMID>
  </reference>
  <reference>
    <citation>Bosques-Padilla FJ, Sandoval-García ER, Martínez-Vázquez MA, Garza-González E, Maldonado-Garza HJ. [Epidemiology and clinical characteristics of ulcerative colitis in north-eastern Mexico]. Rev Gastroenterol Mex. 2011 Jan-Mar;76(1):34-8. Spanish.</citation>
    <PMID>21592901</PMID>
  </reference>
  <reference>
    <citation>[Clinical guidelines for the diagnosis and treatment of chronic ulcerative colitis (CUC). Diagnosis. Usefulness of clinical data and laboratory analysis]. Rev Gastroenterol Mex. 2007 Jul-Sep;72(3):298-9. Spanish.</citation>
    <PMID>18402220</PMID>
  </reference>
  <reference>
    <citation>López-Rosés L, Olivencia-Palomar P. Colonoscopia. Rev. esp. enferm. dig. 100(6): 372-372; 2008.</citation>
  </reference>
  <reference>
    <citation>Martinez-Benitez, B. Características morfológicas de la enfermedad intestinal inflamatoria idiopática. En: Yamamoto-Furusho, JK. Enfermedad Inflamatoria Intestinal: Aspectos básicos y clínicos.2010; México, D.F: Alfil</citation>
  </reference>
  <reference>
    <citation>Villeda-Ramirez M.A. Etiopatogenia de la enfermedad inflamatoria intestinal. En: Yamamoto-Furusho, JK.. Enfermedad Inflamatoria Intestinal: Aspectos básicos y clínicos. 2010; México, D.F: Alfil</citation>
  </reference>
  <reference>
    <citation>World Healh Organization. National policy on traditional medicine and regulation of herbal medicines .Report of a WHO global survey. Geneve 2005</citation>
  </reference>
  <reference>
    <citation>Wild GE, Drozdowski L, Tartaglia C, Clandinin MT, Thomson AB. Nutritional modulation of the inflammatory response in inflammatory bowel disease--from the molecular to the integrative to the clinical. World J Gastroenterol. 2007 Jan 7;13(1):1-7. Review.</citation>
    <PMID>17206749</PMID>
  </reference>
  <reference>
    <citation>Atherton P. Aloe vera revisited. British Journal of Phytotherapy 1998; 4(4): 176-183.</citation>
  </reference>
  <reference>
    <citation>Holdsworth DK. Chromones in aloe species. I. Aloesin--a C-glucosyl-7-hydroxychromone. Planta Med. 1971 Apr;19(4):322-5.</citation>
    <PMID>5573544</PMID>
  </reference>
  <reference>
    <citation>Siddharthan K. Health insurance coverage of the immigrant elderly. Inquiry. 1991 Winter;28(4):403-12.</citation>
    <PMID>1761313</PMID>
  </reference>
  <reference>
    <citation>Avila H, Rivero J, Herrera F, Fraile G. Cytotoxicity of a low molecular weight fraction from Aloe vera (Aloe barbadensis Miller) gel. Toxicon. 1997 Sep;35(9):1423-30.</citation>
    <PMID>9403965</PMID>
  </reference>
  <reference>
    <citation>Curciarello J, De Ortúzar S, Borzi S, Bosia D. [Severe acute hepatitis associated with intake of Aloe vera tea]. Gastroenterol Hepatol. 2008 Aug-Sep;31(7):436-8. Spanish.</citation>
    <PMID>18783689</PMID>
  </reference>
  <reference>
    <citation>Bottenberg MM, Wall GC, Harvey RL, Habib S. Oral aloe vera-induced hepatitis. Ann Pharmacother. 2007 Oct;41(10):1740-3. Epub 2007 Aug 28.</citation>
    <PMID>17726067</PMID>
  </reference>
  <reference>
    <citation>Rabe C, Musch A, Schirmacher P, Kruis W, Hoffmann R. Acute hepatitis induced by an Aloe vera preparation: a case report. World J Gastroenterol. 2005 Jan 14;11(2):303-4.</citation>
    <PMID>15633238</PMID>
  </reference>
  <reference>
    <citation>El-Shemy HA, Aboul-Soud MA, Nassr-Allah AA, Aboul-Enein KM, Kabash A, Yagi A. Antitumor properties and modulation of antioxidant enzymes' activity by Aloe vera leaf active principles isolated via supercritical carbon dioxide extraction. Curr Med Chem. 2010;17(2):129-38. Review.</citation>
    <PMID>19941474</PMID>
  </reference>
  <reference>
    <citation>Kim K, Kim H, Kwon J, Lee S, Kong H, Im SA, Lee YH, Lee YR, Oh ST, Jo TH, Park YI, Lee CK, Kim K. Hypoglycemic and hypolipidemic effects of processed Aloe vera gel in a mouse model of non-insulin-dependent diabetes mellitus. Phytomedicine. 2009 Sep;16(9):856-63. doi: 10.1016/j.phymed.2009.02.014. Epub 2009 Mar 19.</citation>
    <PMID>19303272</PMID>
  </reference>
  <reference>
    <citation>Davis RH, Donato JJ, Hartman GM, Haas RC. Anti-inflammatory and wound healing activity of a growth substance in Aloe vera. J Am Podiatr Med Assoc. 1994 Feb;84(2):77-81.</citation>
    <PMID>8169808</PMID>
  </reference>
  <reference>
    <citation>Davis RH, Leitner MG, Russo JM, et al. Biological activity of Aloe vera. Med Sci Res ; 15: 235, 1987b.</citation>
  </reference>
  <reference>
    <citation>Guo J, Xiao B, Zhang S, Liu D, Liao Y, Sun Q. Growth inhibitory effects of gastric cancer cells with an increase in S phase and alkaline phosphatase activity repression by aloe-emodin. Cancer Biol Ther. 2007 Jan;6(1):85-8.</citation>
    <PMID>17172820</PMID>
  </reference>
  <reference>
    <citation>Stochastic ESR analysis of rat liver and hepatoma mitochondrial lipids. Biophys Struct Mech. 1978 Apr 13;4(2):111-4.</citation>
    <PMID>206295</PMID>
  </reference>
  <reference>
    <citation>Hatano T, Kusuda M, Inada K, Ogawa TO, Shiota S, Tsuchiya T, Yoshida T. Effects of tannins and related polyphenols on methicillin-resistant Staphylococcus aureus. Phytochemistry. 2005 Sep;66(17):2047-55. Review.</citation>
    <PMID>16153408</PMID>
  </reference>
  <reference>
    <citation>Saccù D, Bogoni P, Procida G. Aloe exudate: characterization by reversed phase HPLC and headspace GC-MS. J Agric Food Chem. 2001 Oct;49(10):4526-30.</citation>
    <PMID>11599983</PMID>
  </reference>
  <reference>
    <citation>Speranza G, Morelli CF, Tubaro A, Altinier G, Durì L, Manitto P. Aloeresin I, an anti-inflammatory 5-methylchromone from cape aloe. Planta Med. 2005 Jan;71(1):79-81.</citation>
    <PMID>15678379</PMID>
  </reference>
  <reference>
    <citation>León Sarabia JE, Rosales Clares V, Rosales Clares RA. Alternativas terapéuticas para pacientes portadores de colitis idiopática utilizando aloe vera l. (sábila). Una experiencia. REV CUBANA PLANT MED.3(3):102-5,1999.</citation>
  </reference>
  <reference>
    <citation>Langmead L, Makins RJ, Rampton DS. Anti-inflammatory effects of aloe vera gel in human colorectal mucosa in vitro. Aliment Pharmacol Ther. 2004 Mar 1;19(5):521-7.</citation>
    <PMID>14987320</PMID>
  </reference>
  <results_reference>
    <citation>Gower-Rousseau C, Salomez JL, Dupas JL, Marti R, Nuttens MC, Votte A, Lemahieu M, Lemaire B, Colombel JF, Cortot A. Incidence of inflammatory bowel disease in northern France (1988-1990). Gut. 1994 Oct;35(10):1433-8.</citation>
    <PMID>7959201</PMID>
  </results_reference>
  <results_reference>
    <citation>Yamamoto-Furusho JK. Clinical epidemiology of ulcerative colitis in Mexico: a single hospital-based study in a 20-year period (1987-2006). J Clin Gastroenterol. 2009 Mar;43(3):221-4. doi: 10.1097/MCG.0b013e31817a76b4.</citation>
    <PMID>19057395</PMID>
  </results_reference>
  <results_reference>
    <citation>Knigge KL. Inflammatory bowel disease. Clin Cornerstone. 2002;4(4):49-60. Review.</citation>
    <PMID>12739326</PMID>
  </results_reference>
  <results_reference>
    <citation>Yamamoto-Furusho ,JK, Villalobos, JJ, Olvera, MA, Valdovinos, MA. Colitis ulcerosa crónica inespecífica (CUCI). Gastroenterología. 59. México, Ed. Méndez. 2006; 401-4.</citation>
  </results_reference>
  <results_reference>
    <citation>Bousoño C, Ramos E. Enfermedad Inflamatoria Intestinal. Bol Pediatr 46 (1): 91-99, 2006.</citation>
  </results_reference>
  <results_reference>
    <citation>Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet. 2007 May 12;369(9573):1641-57. Review.</citation>
    <PMID>17499606</PMID>
  </results_reference>
  <results_reference>
    <citation>Kandice, LK. Inflammatory Bowel Disease. Clinical Cornertone. Lower GI Disorders. 2002; 4(4);49-60.</citation>
  </results_reference>
  <results_reference>
    <citation>Feagan BG, Greenberg GR, Wild G, Fedorak RN, Paré P, McDonald JW, Dubé R, Cohen A, Steinhart AH, Landau S, Aguzzi RA, Fox IH, Vandervoort MK. Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. N Engl J Med. 2005 Jun 16;352(24):2499-507.</citation>
    <PMID>15958805</PMID>
  </results_reference>
  <results_reference>
    <citation>Podolsky DK. Inflammatory bowel disease. N Engl J Med. 2002 Aug 8;347(6):417-29. Review.</citation>
    <PMID>12167685</PMID>
  </results_reference>
  <results_reference>
    <citation>Fonseca-Camarillo GC, Villeda-Ramírez MA, Sánchez-Muñoz F, Barreto-Zúñiga R, Domínguez-López A, Uribe-Esquivel M, Yamamoto-Furusho JK. [IL-6 and TNF-α gene expression in the rectal mucosal of patients with chronic idiopathic ulcerative colitis and controls]. Rev Gastroenterol Mex. 2009 Oct-Dec;74(4):334-40. Spanish.</citation>
    <PMID>20423763</PMID>
  </results_reference>
  <results_reference>
    <citation>Mañé Almero J. [In vivo experimental models of inflammatory bowel disease and colorectal cancer]. Nutr Hosp. 2007 Mar-Apr;22(2):178-89. Review. Spanish.</citation>
    <PMID>17416034</PMID>
  </results_reference>
  <results_reference>
    <citation>Blonski W, Buchner AM, Lichtenstein GR. Inflammatory bowel disease therapy: current state-of-the-art. Curr Opin Gastroenterol. 2011 Jul;27(4):346-57. doi: 10.1097/MOG.0b013e328347aef3. Review.</citation>
    <PMID>21654383</PMID>
  </results_reference>
  <results_reference>
    <citation>Park MY, Kwon HJ, Sung MK. Intestinal absorption of aloin, aloe-emodin, and aloesin; A comparative study using two in vitro absorption models. Nutr Res Pract. 2009 Spring;3(1):9-14. doi: 10.4162/nrp.2009.3.1.9. Epub 2009 Mar 31.</citation>
    <PMID>20016696</PMID>
  </results_reference>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 31, 2013</study_first_submitted>
  <study_first_submitted_qc>February 1, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 4, 2013</study_first_posted>
  <last_update_submitted>February 1, 2013</last_update_submitted>
  <last_update_submitted_qc>February 1, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 4, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Institute of Medical Sciences and Nutrition, Salvador Zubiran</investigator_affiliation>
    <investigator_full_name>Jesús Kazuo Yamamoto Furusho</investigator_full_name>
    <investigator_title>MD PhD</investigator_title>
  </responsible_party>
  <keyword>Ulcerative Colitis</keyword>
  <keyword>Aloe Vera</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

